| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/CLPT.1993.132 |
| P698 | PubMed publication ID | 8354028 |
| P2093 | author name string | B D Kahan | |
| A Lindholm | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacokinetics | Q323936 |
| cyclosporine | Q367700 | ||
| P304 | page(s) | 205-218 | |
| P577 | publication date | 1993-08-01 | |
| P1433 | published in | Clinical Pharmacology & Therapeutics | Q1101529 |
| P1476 | title | Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. | |
| P478 | volume | 54 |
| Q39024541 | A Systematic Literature Review Approach to Estimate the Therapeutic Index of Selected Immunosuppressant Drugs After Renal Transplantation |
| Q46949978 | A case report of unresectable gallbladder cancer that responded remarkably to the combination of thalidomide, celecoxib, and gemcitabine |
| Q51955888 | A drug transporter for all ages? ABCB1 and the developmental pharmacogenetics of cyclosporine. |
| Q44136543 | A limited sampling strategy for the estimation of 12-hour Neoral systemic drug exposure in heart transplant recipients |
| Q41177624 | A new microemulsion formulation of cyclosporin: pharmacokinetic and clinical features |
| Q35177677 | A pharmacokinetic and clinical review of the potential clinical impact of using different formulations of cyclosporin A. Berlin, Germany, November 19, 2001. |
| Q32139934 | A retrospective analysis of mycophenolic acid and cyclosporin concentrations with acute rejection in renal transplant recipients |
| Q38089593 | A review on therapeutic drug monitoring of immunosuppressant drugs. |
| Q52080444 | Abbreviated tacrolimus area-under-the-curve monitoring for renal transplant recipients. |
| Q74685673 | Abbreviating area under the curves further: a practical approach to monitoring extended pharmacokinetics with Neoral |
| Q44146556 | Adequate early cyclosporin exposure is critical to prevent renal allograft rejection: patients monitored by absorption profiling |
| Q44971336 | An economic model of 2-hour post-dose ciclosporin monitoring in renal transplantation |
| Q35710975 | Application of cyclosporine in renal transplantation: experience at the University of Padua |
| Q52237032 | Area under the concentration curve values in pediatric liver transplant recipients on cyclosporin microemulsion formulation. |
| Q46843863 | Assessment of cyclosporine pharmacokinetic parameters to facilitate conversion from C0 to C2 monitoring in heart transplant recipients |
| Q44577615 | Assessment of cyclosporine therapeutic monitoring with C2 concentrations in stable renal allograft recipients. |
| Q44651731 | Basiliximab widens the therapeutic window for AUC-monitored neoral therapy early after kidney transplantation |
| Q35827273 | Bayesian estimation of cyclosporin exposure for routine therapeutic drug monitoring in kidney transplant patients |
| Q44707786 | Beneficial pharmacokinetic interaction between cyclosporine and itraconazole in renal transplant recipients |
| Q33636607 | Bioequivalence criteria for cyclosporine. |
| Q46554256 | Blood cyclosporine level soon after kidney transplantation is a major determinant of rejection: insights from the Mycophenolate Steroid-Sparing Trial. |
| Q35284185 | Bypassing the EPR effect with a nanomedicine harboring a sustained-release function allows better tumor control |
| Q44568274 | C0/C2 cyclosporine levels monitoring in renal transplantation |
| Q45197127 | C2 is superior to C0 as predictor of renal toxicity and rejection risk profile in stable heart transplant recipients |
| Q57893157 | C2 monitoring of cyclosporine in stable heart transplant patients after two daily and three daily doses |
| Q46468643 | C2 monitoring of cyclosporine in stable renal transplant patients results in lower costs and improved renal function |
| Q77369604 | C2 single-point sampling to evaluate cyclosporine exposure in long-term renal transplant recipients |
| Q78514321 | C2 therapeutic drug monitoring of cyclosporine: sources of variability |
| Q44173471 | Can a pharmacokinetic approach to immunosuppression eliminate ethnic disparities in renal allograft outcome? |
| Q43552908 | Choosing the right dose of new immunossuppressive drugs for new populations: importance of pharmacokinetic studies |
| Q36922221 | Ciclosporin kinetics in children after stem cell transplantation |
| Q73573589 | Circadian variations in cyclosporine C2 concentrations during the first 2 weeks after liver transplantation |
| Q64885429 | Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis. |
| Q40860727 | Clinical pharmacokinetics in the 21st century. Does the evidence support definitive outcomes? |
| Q44577665 | Clinical pharmacokinetics of tacrolimus in heart transplantation: new strategies of monitoring |
| Q78693513 | Clinical use of c2 monitoring in long-term liver transplant recipients |
| Q73208876 | Comparative bioavailability evaluation of two cyclosporine oral formulations in healthy Mexican volunteers |
| Q77176309 | Comparative bioavailability of Neoral and Sandimmune in cardiac transplant recipients over 1 year |
| Q73301301 | Comparative pharmacokinetic study of Neoral vs Sandimmun in Japanese stable renal allograft recipients |
| Q43640057 | Comparative pharmacokinetic study of neoral versus Sandimmun in Japanese stable renal allograft recipients |
| Q41888898 | Comparison of architect I 2000 for determination of cyclosporine with axsym |
| Q73277940 | Comparison of efficacy, safety, and tolerability of Neoral vs Sandimmun in de novo renal transplant patients over 24 months' treatment |
| Q77758310 | Considerations concerning generic formulations of immunosuppressive drugs |
| Q33542686 | Contemporary immunosuppression in renal transplant recipients: one size does not fit all. |
| Q73013008 | Conversion of C-0 to C-2 monitoring of cyclosporine in stable kidney transplant patients |
| Q77724875 | Conversion of stable renal transplant recipients from Sandimmune to Sang-35, a Neoral-equivalent cyclosporine formulation, using a dose-adjusted method |
| Q77175891 | Conversion of stable renal transplant recipients from Sandimmune to Sang-35, a novel cyclosporine formulation, using a dose-normalized equivalence method |
| Q43906478 | Correlations between cyclosporine concentrations at 2 hours post-dose and trough levels with functional outcomes in de novo lung transplant recipients |
| Q53362419 | CsA exposure is associated with acute GVHD and relapse in children after SCT. |
| Q73194059 | Current opinions on therapeutic drug monitoring of immunosuppressive drugs |
| Q44520611 | Cyclosporin C(2) and C(0) concentration monitoring in stable, long-term heart transplant recipients receiving metabolic inhibitors |
| Q33646051 | Cyclosporin microemulsion (Neoral). A pharmacoeconomic review of its use compared with standard cyclosporin in renal and hepatic transplantation |
| Q40961292 | Cyclosporin. A review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral). |
| Q34439272 | Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation |
| Q61764257 | Cyclosporine A monitoring ? how to account for twice and three times daily dosing |
| Q77369580 | Cyclosporine A: peak or trough level monitoring in renal transplant recipients? |
| Q35711226 | Cyclosporine in thoracic organ transplantation |
| Q77369585 | Cyclosporine level: which single-point estimation of drug level is the best? |
| Q44511304 | Cyclosporine lymphocyte versus whole blood pharmacokinetic monitoring: correlation with histological findings |
| Q44051279 | Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation |
| Q79997089 | Cyclosporine monitoring in stable, long-term, pediatric kidney transplant recipients: the value of C2 determination |
| Q73303986 | Cyclosporine trough levels in diabetic and nondiabetic renal transplant patients |
| Q32079834 | Cyclosporine-loaded polycaprolactone nanoparticles: immunosuppression and nephrotoxicity in rats. |
| Q36242864 | Cyclosporine: from renal transplantation to autoimmune diseases |
| Q33636552 | Cyclosporine: the case for expanding bioequivalence criteria to include measures of individual bioequivalence in relevant population subsets |
| Q77175909 | Cyclosporine: the principal immunosuppressant for renal transplantation |
| Q44066573 | Cytomegalovirus and cyclosporin-induced gingival overgrowth in children with liver grafts |
| Q50881033 | Demographic considerations in tacrolimus pharmacokinetics. |
| Q81631178 | Determination of initial i.v. CYA dosage to achieve target AUC values in pediatric hematopoietic stem cell transplant patients |
| Q42283823 | Developmental pharmacokinetics of ciclosporin--a population pharmacokinetic study in paediatric renal transplant candidates. |
| Q43923270 | Diurnal cyclosporine dosing optimizes exposure and reduces the risk of acute rejection after kidney transplantation |
| Q46857787 | Do we have the same clinical results with Neoral and Equoral treatment in kidney transplant recipients? A pilot study |
| Q73674314 | Effect of grapefruit juice on pharmacokinetics of microemulsion cyclosporine in African American subjects compared with Caucasian subjects: does ethnic difference matter? |
| Q42674776 | Effect of plasma uric acid on pharmacokinetics of cyclosporine A in living-related renal transplant recipients and pharmacokinetic study in rats with experimental hyperuricaemia |
| Q77176546 | Effect of variability of cyclosporine pharmacokinetics on long-term renal allograft survival |
| Q57943257 | Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study |
| Q46512714 | Evaluation of appropriate blood level in continuous intravenous infusion from trough concentrations after oral administration based on area under trough level in tacrolimus and cyclosporine therapy |
| Q42169506 | Evaluation of cyclosporine C2 levels in long-term stable renal allograft recipients. |
| Q44256939 | Evaluation of different sampling times for best prediction of cyclosporine area under the curve in renal transplant recipients |
| Q35711203 | Evolution of immunosuppression in liver transplantation: contribution of cyclosporine |
| Q35711382 | Evolution of the therapeutic drug monitoring of cyclosporine |
| Q79819422 | Experience with cyclosporine |
| Q35711274 | Experience with cyclosporine in heart transplantation |
| Q44812510 | Experience with cyclosporine: approaching the therapeutic window for C2 levels in maintenance kidney transplant recipients |
| Q35711395 | Experience with therapeutic drug monitoring of cyclosporine |
| Q43888378 | Factors influencing cyclosporine blood concentration-dose ratio |
| Q46843919 | Feasibility of C2 monitoring in Korean renal transplantation |
| Q37945385 | Fifty years in the vineyard of transplantation: looking back |
| Q35711582 | Future directions in immunosuppression |
| Q36073209 | Generic cyclosporine formulations: more open questions than answers |
| Q77175787 | Generic substitution for cyclosporine: what should we be looking for in new formulations? |
| Q57212294 | High intra-individual variability of cyclosporine pharmacokinetics in lung transplant recipients without cystic fibrosis |
| Q77175762 | High variability of drug exposure: a biopharmaceutic risk factor for chronic rejection |
| Q35795075 | How cyclosporine modifies histological and molecular events in the vascular wall during chronic rejection of rat cardiac allografts. |
| Q44723684 | Immunosuppression (Neoral vs Sandimmune) in pediatric kidney transplantation |
| Q38154197 | Immunosuppression and allograft rejection following lung transplantation: evidence to date |
| Q72753027 | Immunosuppressive agents |
| Q34025202 | Impact of absorption profiling on efficacy and safety of cyclosporin therapy in transplant recipients. |
| Q44256929 | Impact of cyclosporine dosing frequency on graft function and survival after the conversion from sandimmun to neoral in stable kidney transplanted patients |
| Q35710879 | Impact of cyclosporine in the development of immunosuppressive therapy |
| Q35711265 | Impact of cyclosporine on cardiac transplantation in Berlin |
| Q73625447 | Improved absorption and bioavailability of cyclosporine A from a microemulsion formulation in lung transplant recipients affected with cystic fibrosis |
| Q72343561 | Improved absorption of cyclosporin A from a new microemulsion formulation: implications for dosage and monitoring |
| Q46415904 | Improved pharmacokinetic monitoring of tacrolimus exposure after pediatric renal transplantation |
| Q39018542 | In vitro efficacy of polysaccharide-based nanoparticles containing disease-modifying antirheumatic drugs |
| Q43003658 | Increased incidence of early de novo cancer in liver graft recipients treated with cyclosporine: an association with C2 monitoring and recipient age. |
| Q28244228 | Influence of different allelic variants of the CYP3A and ABCB1 genes on the tacrolimus pharmacokinetic profile of Chinese renal transplant recipients |
| Q59157789 | Influence of drug formulation on utilization and outcomes: Neoral and monitoring by sparse sample area under the curve |
| Q77932301 | Influence of glycerol-induced acute renal failure on the pharmacokinetics of cyclosporin in rats |
| Q54453864 | Influence of the MDR1 haplotype and CYP3A5 genotypes on cyclosporine blood level in Chinese renal transplant recipients. |
| Q73905430 | Introduction. Neoral use in organ transplantation |
| Q44651773 | Ketoconazole alters cyclosporine pharmacokinetic profile and may predispose to acute rejection |
| Q44405616 | Limited sampling strategies using Bayesian estimation or multilinear regression for cyclosporin AUC(0-12) monitoring in cardiac transplant recipients over the first year post-transplantation. |
| Q52998114 | Long-term experience with Sandimmun Neoral: results in de novo and stable renal transplant patients after 24-month treatment. The German Neoral Study Group. |
| Q44707802 | Long-term predictive value of cyclosporine microemulsion C2 level for chronic renal allograft dysfunction. |
| Q42604709 | Longitudinal evaluation of the pharmacokinetics of cyclosporin microemulsion (Neoral) in pediatric renal transplant recipients and assessment of C2 level as a marker for absorption. |
| Q77175872 | Low exposure to cyclosporine is a risk factor for the occurrence of chronic rejection after kidney transplantation |
| Q73869051 | Mass conversion from Sandimmun to Sandimmun Neoral: 1 1/2-year experience |
| Q43875084 | Maximum a posteriori Bayesian estimation of oral cyclosporin pharmacokinetics in patients with stable renal transplants |
| Q33937533 | Methods for clinical monitoring of cyclosporin in transplant patients. |
| Q42422945 | Nanoparticles made of multi-block copolymer of lactic acid and ethylene glycol containing periodic side-chain carboxyl groups for oral delivery of cyclosporine A. |
| Q43553097 | Neoral C-2 monitoring in cardiac transplant patients |
| Q33920671 | Neoral absorption profiling: an evolution in effectiveness. |
| Q77632839 | Neoral as the initial immunosuppressant in liver transplantation; conversion from Sandimmune to Neoral in stable patients |
| Q35064432 | Neoral monitoring 2 hours post-dose and the pediatric transplant patient |
| Q33920658 | Neoral use in the pediatric transplant recipient |
| Q33920652 | Neoral use in the renal transplant recipient |
| Q51018547 | New strategies of cyclosporine monitoring in heart transplantation: initial results. |
| Q33346257 | On the action of cyclosporine A, rapamycin and tacrolimus on M. avium including subspecies paratuberculosis |
| Q44812477 | Optimization of cyclosporine for liver transplantation |
| Q57703989 | Optimization of cyclosporine therapy in kidney transplantation |
| Q77176126 | Optimization of cyclosporine therapy in liver transplantation |
| Q43828405 | Optimization of cyclosporine therapy in the Neoral era: abbreviated AUC, single blood sampling? |
| Q52237037 | Optimization of cyclosporine therapy with new therapeutic drug monitoring strategies: report from the International Neoral TDM Advisory Consensus Meeting (Vancouver, November 1997). |
| Q36496718 | Optimizing the use of cyclosporin in allogeneic stem cell transplantation |
| Q83364643 | Pediatric liver transplantation |
| Q59531446 | Pharmacokinetic and pharmacodynamic correlations of cyclosporine therapy in stable renal transplant patients: evaluation of long-term target C2 |
| Q46594272 | Pharmacokinetic monitoring of intravenous cyclosporine A in pediatric stem-cell transplant recipients. The trough level is not enough |
| Q34610933 | Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part I |
| Q73800778 | Pharmacokinetic validation of neoral absorption profiling |
| Q82596474 | Pharmacokinetics of cyclosporine A at a high-peak concentration of twice-daily infusion and oral administration in allogeneic haematopoietic stem cell transplantation |
| Q79715603 | Pharmacokinetics of neoral in stable renal transplant recipients with long-term diabetes mellitus |
| Q77176561 | Pharmacokinetics of oral cyclosporine microemulsion formulation (Neoral) in children awaiting renal transplantation |
| Q35711368 | Pharmacologic monitoring and outcomes of cyclosporine |
| Q35710811 | Pharmacology of calcineurin antagonists |
| Q43875081 | Population pharmacokinetic model to predict steady-state exposure to once-daily cyclosporin microemulsion in renal transplant recipients |
| Q46830629 | Population pharmacokinetic study of cyclosporine in Chinese renal transplant recipients |
| Q51531729 | Population pharmacokinetics of cyclosporine in Korean adults undergoing living-donor kidney transplantation. |
| Q36484956 | Population pharmacokinetics of cyclosporine in chinese cardiac transplant recipients |
| Q35810035 | Potential clinical implications of substitution of generic cyclosporine formulations for cyclosporine microemulsion (Neoral) in transplant recipients. |
| Q42726668 | Potential of dried blood self-sampling for cyclosporine c(2) monitoring in transplant outpatients |
| Q44491037 | Pre- and postrenal transplantation pharmacokinetics of cyclosporine microemulsion |
| Q77958746 | Predictive value of cyclosporine blood levels during the absorption phase to estimate the area under the curve in stable renal transplant patients |
| Q44373816 | Predictive value of pretransplantation cyclosporine pharmacokinetic studies on initial post-transplantation dosing in pediatric kidney allograft recipients |
| Q40880337 | Prevention of transplant rejection: current treatment guidelines and future developments |
| Q46435095 | Racial variation in dosage requirements of tacrolimus |
| Q44051282 | Randomized, international study of cyclosporine microemulsion absorption profiling in renal transplantation with basiliximab immunoprophylaxis |
| Q41615861 | Reduced intrapatient variability of cyclosporine pharmacokinetics in renal transplant recipients switched from oral Sandimmune to Neoral |
| Q33636611 | Relationship of pharmacokinetics to clinical outcomes |
| Q72753037 | Renal transplantation |
| Q45046027 | Renal transplants with delayed graft function show decreased renal function despite monitoring with postabsorptive levels |
| Q38501680 | Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment |
| Q34069142 | Review of select transplant subpopulations at high risk of failure from standard immunosuppressive therapy |
| Q77176891 | Role of therapeutic drug monitoring of rapamycin |
| Q73185884 | Sandimmune to Neoral conversion and value of abbreviated AUC monitoring in stable pediatric kidney transplant recipients |
| Q41549146 | Switching between cyclosporin formulations. What are the risks? |
| Q44634059 | The effect of ketoconazole on whole blood and skin ciclosporin concentrations in dogs |
| Q44220310 | The effect of two different cyclosporine formulations on the long-term progression to chronic rejection in renal allograft recipients |
| Q74182585 | The effects of relative timing of sirolimus and cyclosporine microemulsion formulation coadministration on the pharmacokinetics of each agent |
| Q77369533 | The evolution of therapeutic drug monitoring of cyclosporine |
| Q44812503 | The impact of cyclosporine on the development of immunosuppressive therapy: perspective from a transplant nephrologist involved with the development of C2. |
| Q58812374 | The influence of CYP3A gene polymorphisms on cyclosporine dose requirement in renal allograft recipients |
| Q44256944 | The roles of C4 and AUC0-4 in monitoring of tacrolimus in stable kidney transplant patients |
| Q71437985 | The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients |
| Q35710888 | The use of cyclosporine in renal transplantation |
| Q41201521 | The use of therapeutic drug monitoring to optimise immunosuppressive therapy |
| Q40648516 | Therapeutic drug monitoring and patient outcome. A review of the issues |
| Q38206952 | Therapeutic drug monitoring in pediatric renal transplantation |
| Q35711356 | Therapeutic drug monitoring of cyclosporine |
| Q44812506 | Therapeutic drug monitoring of cyclosporine |
| Q35711332 | Therapeutic drug monitoring of cyclosporine: 20 years of progress |
| Q34599623 | Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. |
| Q33610775 | Therapeutic drug monitoring of immunosuppressant drugs. |
| Q43552996 | Therapeutic drug monitoring of sirolimus for optimal renal transplant outcomes |
| Q33332141 | Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity |
| Q79819511 | Therapeutic monitoring of cyclosporine in kidney transplantation: the Halifax experience |
| Q33661554 | Therapeutic strategies for optimal use of novel immunosuppressants |
| Q77369576 | Three-hour postdose cyclosporine level monitoring: less rejection and more nephrotoxicity? |
| Q44822760 | Two-hour post-dose cyclosporin A levels in adolescent renal transplant recipients in the late post-transplant period |
| Q44133337 | Two-hour post-dose cyclosporine level is a better predictor than trough level of acute rejection of renal allografts |
| Q44437918 | Two-year results of multicenter phase III trials on the effect of the addition of sirolimus to Cyclosporine-based immunosuppressive regimens in renal transplantation |
| Q38660544 | Update on pathogenesis and predictors of response of therapeutic strategies used in inflammatory bowel disease |
| Q52087593 | Ursodeoxycholic acid modulates cyclosporin A oral absorption in liver transplant recipients. |
| Q77632493 | Use of cyclosporine MEPC (Neoral) in heart transplant recipients |
| Q35710903 | Use of cyclosporine in renal transplantation |
| Q79819453 | Use of cyclosporine in renal transplantation |
| Q38464536 | Use of cyclosporine pharmacokinetic profiles in an antibody induction protocol reduces early acute rejection rates in recipients of primary cadaveric renal allografts |
| Q71719576 | Which cyclosporin formulation? |
Search more.